Explore our core technological pipelines engineered to advance botanical candidates from raw matrix screening to validated commercial production.
In botanical contract manufacturing, the benchmark of "Highest Standards" is not merely an aspirational marketing claim; it represents a stringent scientific discipline governed by reproducible analytical metrics, molecular-level quality control, and rigorous pharmacopeial compliance.
Moving beyond generic single-marker assays, our highest-standard protocol deploys high-performance thin-layer chromatography (HPTLC) and high-performance liquid chromatography (HPLC) multi-wavelength fingerprinting. This captures the complete phytochemical matrix, guaranteeing that secondary metabolites, synergistic flavonoids, and saponins remain completely unadulterated from harvest to final packaging.
Every commercial batch is screened against ultra-trace threshold limits utilizing inductively coupled plasma mass spectrometry (ICP-MS) and triple-quadrupole gas chromatography (GC-MS/MS). We enforce European Pharmacopoeia (Ph. Eur. 2.8.13) and USP <561> compliance, certifying total absence of organochlorine pesticides, aflatoxins, polycyclic aromatic hydrocarbons (PAHs), and toxic heavy metals.
Rooted in Quality by Design (QbD) principles (ICH Q8, Q9, Q10), critical process parameters (CPPs)—including hydrodynamic flow rate, solvent extraction temperature, vacuum evaporation enthalpy, and spray-drying inlet/outlet moisture balances—are continuously logged to eliminate batch-to-batch variation across high-volume production cycles.
The global natural medicine, botanical drug, and evidence-backed nutraceutical market is undergoing an unprecedented structural transition driven by stringent regulatory frameworks and shifting consumer preferences toward clinically substantiated bioactives.
Historically, global botanical supply chains operated within an unstandardized paradigm: crude raw materials were harvested with little agronomic control, coarsely extracted to arbitrary percentages, and traded as generic commodities on open spot markets. This legacy model has broken down. Regulatory bodies worldwide—including the US FDA under 21 CFR Part 111/314 (Botanical Drug Guidance), the European Medicines Agency (EMA) through the Committee on Herbal Medicinal Products (HMPC), and the Australian TGA—now demand complete traceability, quantitative secondary metabolite fingerprints, and validated therapeutic mechanism profiles.
Furthermore, Tier-1 pharmaceutical and premium dietary supplement brands are actively migrating away from multi-vendor fragmentation. Contracting an analytical laboratory in one country, an extraction facility in another, and an animal pharmacology laboratory in a third introduces massive tech-transfer risks, IP leakage, and escalating supply-chain friction. Integrated CRO/CDMO entities capable of handling the entire pipeline—from plant genomics and agronomic origin screening to pilot crystallization and cGMP dosage manufacturing—have emerged as the undisputed backbone of modern botanical commercialization.
| Jurisdiction | Core Regulatory Framework | OEM Technical Requirement |
|---|---|---|
| United States | FDA 21 CFR 111 / 211 / Botanical Drug Guidance | Batch identity testing via HPTLC/HPLC, dissolution profiles, full cGMP audit trails. |
| European Union | EMA HMPC / Directive 2004/24/EC / Ph. Eur. | Validated chromatographic fingerprinting, genotoxicity assay packages, strict PAH thresholds. |
| Asia-Pacific | NMPA Class 1.1–1.3 Botanical Registration / TGA | Classic formula modernization data, toxicological profiling (LD50), multi-center clinical validation. |
| Global Global Halal/Kosher | MUI, JAKIM, Star-K, OU Certifications | 100% plant-derived processing, solvent-free ethanol/water recovery, dedicated production lines. |
Operating from Changsha, Hunan—the geographic epicenter of botanical raw materials and phytomedical science in China—MedGence bridges agricultural provenance with state-of-the-art pharmaceutical automation.
Our raw material procurement is decoupled from volatile open brokers. Through contracted Good Agricultural and Collection Practices (GACP) farming alliances spanning diverse ecological microclimates, we dictate soil pH, fertilization protocols, harvesting timelines, and field drying kinetics. This guarantees absolute origin authenticity and eliminates adulteration at the very point of germination.
Unlike Western contract labs that must outsource industrial scale-up to overseas partners, our technical ecosystem merges analytical screening, pilot extraction suites (50L–1,000L), and automated commercial manufacturing halls (10,000L+ extraction lines). A laboratory validation batch can be scaled to ton-level cGMP commercial throughput within 6 to 8 weeks, slashing time-to-market by over 50%.
By leveraging China's dense industrial equipment clusters, state-of-the-art clean-energy utilities, and concentrated petrochemical and reagent supply chains, MedGence provides Tier-1 global pharmaceutical partners with an exceptional price-to-performance ratio without compromising a single dimension of analytical rigor or cGMP compliance.
Our OEM/CDMO services are customized to meet the exact technological, bioavailability, and regulatory expectations of distinct commercial product sectors across major global consumer markets.
Tailored for biopharmaceutical developers pursuing FDA Botanical New Drug Applications (NDAs) or NMPA Class 1.1/1.2 registrations. We engineer hyper-purified single-molecule botanical active pharmaceutical ingredients (APIs), resolve racemic isomers, formulate stable crystalline polymorphs, and compile complete CTD Module 3 chemistry, manufacturing, and controls (CMC) dossiers.
Engineered for high-end consumer health brands requiring substantiated structure-function claims. We formulate standardized extracts with quantified biomarker densities, optimize solubility profiles via micronization and spray-granulation, and deliver robust batch-to-batch stability supported by 36-month real-time stability protocols.
Formulated for international prestige personal care brands. We develop clear, low-color, odor-attenuated, water-soluble botanical actives certified free from synthetic residual solvents. Supported by 3D reconstructed human epidermis (RhE) anti-inflammatory, cellular antioxidant, and elastase-inhibition in vitro data.
Capitalizing on our record of securing 56 hospital preparation registrations, we modernize classic herbal formulas into standardized oral liquids, enteric-coated softgels, and immediate-dissolution micro-granules tailored for clinical applications and hospital-based institutional health systems.
At MedGence, we continuously invest in next-generation analytical platforms, bio-computational screening algorithms, and sustainable green manufacturing technologies to define the future of natural medicine engineering.
Integrating machine-learning ligand-protein docking algorithms to screen our proprietary phytochemical library of over 100,000 herbal isolates against orphan receptors, enzymes, and disease targets, drastically cutting early-stage lead discovery cycles.
Transitioning all commercial extraction suites to subcritical water extraction and closed-loop continuous supercritical CO2 systems with polar co-solvents, achieving 99.8% solvent recovery rates while delivering completely toxic-free extracts.
Overcoming the notorious poor oral bioavailability of natural polyphenols and hydrophobic saponins via targeted self-nanoemulsifying drug delivery systems (SNEDDS), phytosome complexes, and cyclodextrin molecular inclusion complexes.
Deployment of in-line Process Analytical Technology (PAT)—incorporating continuous near-infrared (NIR) spectroscopy and real-time particle-size analyzers—to monitor chemical uniformity and process endpoints in real time across all drying and granulation operations.
Navigating cross-border regulatory submission requirements requires an airtight quality governance architecture. MedGence ensures that every technical dossier, batch record, and certificate of analysis is recognized seamlessly by health authorities globally.
Our regulatory affairs division compiles comprehensive Common Technical Document (CTD) dossiers. We provide Drug Master File (DMF) open-part and closed-part documentation, supporting our overseas pharmaceutical clients' Investigational New Drug (IND) and NDA filings before the US FDA and European national authorities.
All spectrophotometric, chromatographic, and mass spectrometry instruments operate under 21 CFR Part 11 compliant data management architectures. System audit trails, automated timestamping, and multi-tier cryptographic user permissions guarantee absolute data traceability and audit readiness.
We operate exclusively on an entrusted contract research and manufacturing model. Under legally binding mutual Non-Disclosure Agreements (NDAs) enforceable across international jurisdictions, your proprietary botanical formulas, purification steps, and clinical data are quarantined in encrypted air-gapped environments.
Our collaborative track record covers high-tier pharmaceutical enterprises, premier university teaching hospitals, and state medical research institutes.
Tongrentang Group
CR Sanjiu Pharmaceutical
Sunflower Pharmaceutical
Livzon Pharmaceutical
Dihon Pharmaceutical
Golden Throat Holdings
Yangtze River Pharma
Beihai Gofar Chuanshan
Humanwell Healthcare
SCIMYTH Pharma
Hanfang Pharmaceutical
Luoxin Pharmaceutical
Zhongsheng Pharma
Brilliance & Abundance
Apeloa Pharmaceutical
Heng Chang Pharma
Baotou TCM
Kamp Medicine
Santo Pharmaceutical
Kangshou Pharmaceutical
Juwang Pharmaceutical
Tcmages Pharmaceutical
Guizhou Ruihe Pharma
CR Jinchan Pharma
Kangmei Pharmaceutical
Tianjicaotang Pharma
Kingstone Unite Pharma
Shuguang Hospital (Shanghai)
Hunan Prov. TCM Hospital
1st Affil. Hosp. Hunan TCM
2nd Xiangya Hospital (CSU)
2nd Affil. Hosp. Hunan TCM
Zhuzhou Orthopedics TCMIn-depth responses tailored for technical directors, regulatory compliance executives, and strategic procurement teams evaluating contract manufacturing partnerships.
Access our certified preclinical and cGMP manufacturing streams. Choose an engineering module to initiate your custom tech-transfer brief.
